Exodus Point Capital Management, LP Spectrum Pharmaceuticals Inc Transaction History

Exodus Point Capital Management, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$0.38 - $1.07 $9,234 - $26,001	24,300 New	24,300 $18,000
Q1 2022 May 13, 2022	SELL	$0.63 - $1.59 $106,373 - $268,466	-168,847 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$1.27 - $2.42 $135,501 - $258,199	106,694 Added 171.66%	168,847 $214,000
Q3 2021 Nov 15, 2021	BUY	$2.15 - $3.82 $133,628 - $237,424	62,153 New	62,153 $135,000
Q1 2021 May 17, 2021	SELL	$2.9 - $4.09 $71,493 - $100,830	-24,653 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$3.38 - $5.14 $36,335 - $55,255	10,750 Added 77.32%	24,653 $84,000
Q3 2020 Nov 16, 2020	SELL	$2.99 - $4.9 $18,702 - $30,649	-6,255 Reduced 31.03%	13,903 $57,000
Q2 2020 Aug 14, 2020	BUY	$2.11 - $3.38 $42,533 - $68,134	20,158 New	20,158 $68,000
Q1 2020 May 15, 2020	SELL	$1.83 - $3.45 $62,586 - $117,990	-34,200 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$3.5 - $10.35 $82,250 - $243,225	23,500 Added 219.63%	34,200 $124,000
Q3 2019 Nov 14, 2019	BUY	$7.03 - $9.7 $75,221 - $103,789	10,700 New	10,700 $89,000

115K

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.